Atrium Innovations Inc. a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based natural health products, announced today that the Superior Court of Québec (Commercial Division) issued a final order approving the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium for cash consideration of $24.00 per common share by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding convertible debentures.
Earlier this month, the Corporation received confirmation from the U.S. Federal Trade Commission that early termination of the pre-closing waiting period mandated under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had been granted, which allows the parties to proceed to closing. Atrium has also now received from the competition regulatory authorities in Germany, Ireland and Austria clearances or confirmations that the transaction may proceed to closing.
Click below to download the full release.
